Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Huaxiang Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5346-2335; OpenAlex author ID A5019514796. Sources: OpenAlex.

Their work

Papers
47 (first author 12, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
105
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 6 papers · 2019: 10 papers · 2020: 3 papers · 2021: 5 papers · 2022: 4 papers · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 47

  1. [Corrigendum] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. First author DOI 10.3892/ijo.2025.5822↗
  2. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  3. Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. Co-author DOI 10.1016/j.isci.2024.111693↗
  4. Deciphering molecular crosstalk mechanisms between skeletal muscle atrophy and KRAS-mutant pancreatic cancer: a literature review. Co-author DOI 10.21037/hbsn-24-282↗
  5. First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review. Co-author DOI 10.1007/s12672-024-01420-3↗
  6. Construction of S100 family members prognosis prediction model and analysis of immune microenvironment landscape at single-cell level in pancreatic adenocarcin… Co-author DOI 10.1097/js9.0000000000001293↗
  7. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  8. Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. First author DOI 10.1007/s12020-022-03196-4↗
  9. The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis. Co-author DOI 10.1038/s41388-023-02647-0↗
  10. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. Co-author DOI 10.1002/jcla.24517↗
  11. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  12. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  13. Robust Validation and Comprehensive Analysis of a Novel Signature Derived from Crucial Metabolic Pathways of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14071825↗
  14. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33410↗
  15. Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer". Co-author DOI 10.1097/sla.0000000000004538↗
  16. Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR/ERK pathway. Co-author DOI 10.1111/jcmm.16555↗
  17. Activation of the PX1/IL-1β axis in CD41+/CD62P+ platelets enhances pancreatic ductal adenocarcinoma invasion and metastasis Co-author DOI 10.21203/rs.3.rs-307202/v1↗
  18. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Co-author DOI 10.3390/cancers13153678↗
  19. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  20. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Co-author DOI 10.1038/s41388-020-01407-8↗
  21. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. Co-author DOI 10.3748/wjg.v26.i8.828↗
  22. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. First author DOI 10.1002/cam4.1957↗
  23. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2430↗
  24. Angiogenesis in pancreatic cancer: current research status and clinical implications. First author DOI 10.1007/s10456-018-9645-2↗
  25. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2018.10.539↗
  26. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-018-6941-4↗
  27. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-019-07169-2↗
  28. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. First author DOI 10.2147/cmar.s197911↗
  29. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Co-author DOI 10.2174/0929867325666180413101722↗
  30. The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. Co-author DOI 10.7150/jca.30883↗
  31. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. Co-author DOI 10.7150/jca.32072↗
  32. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. Co-author DOI 10.1016/j.hbpd.2018.03.007↗
  33. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  34. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… First author DOI 10.1016/j.surg.2018.01.017↗
  35. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗
  36. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. First author DOI 10.3892/ijo.2018.4269↗
  37. The Significance of Liquid Biopsy in Pancreatic Cancer. First author DOI 10.7150/jca.24591↗
  38. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.08.005↗
  39. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  40. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… Co-author DOI 10.1038/srep19222↗
  41. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. First author DOI 10.18632/oncotarget.6819↗
  42. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. First author DOI 10.1002/ijc.29242↗
  43. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Co-author DOI 10.1016/j.canlet.2015.01.023↗
  44. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000000751↗
  45. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Co-author DOI 10.1007/s00259-014-2688-8↗
  46. Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic canc… Co-author DOI 10.1371/journal.pone.0071189↗
  47. Significance of caveolin-1 regulators in pancreatic cancer. Co-author DOI 10.7314/apjcp.2013.14.8.4501↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 39 shared papers, 2013–2026 · strength 3.64
  2. Liang Liu · 28 shared papers, 2013–2026 · strength 2.56
  3. Chuntao Wu · 29 shared papers, 2013–2026 · strength 2.29
  4. Wenquan Wang · 19 shared papers, 2015–2026 · strength 2.14
  5. Shuo Li · 14 shared papers, 2018–2021 · strength 1.31
  6. Wen-Quan Wang · 17 shared papers, 2013–2020 · strength 1.16
  7. Heli Gao · 12 shared papers, 2018–2022 · strength 1.15
  8. Tianjiao Li · 10 shared papers, 2019–2022 · strength 1.07
  9. He-Li Gao · 10 shared papers, 2018–2026 · strength 1.01
  10. Shi-Rong Zhang · 10 shared papers, 2018–2026 · strength 1.00
  11. Zi-Hao Qi · 10 shared papers, 2016–2026 · strength 0.94
  12. Wuhu Zhang · 9 shared papers, 2019–2022 · strength 0.94
  13. Liang Liu · 8 shared papers, 2019–2023 · strength 0.91
  14. Jin-Zhi Xu · 9 shared papers, 2018–2026 · strength 0.91
  15. Quanxing Ni · 11 shared papers, 2015–2023 · strength 0.86
  16. Wei Jin · 7 shared papers, 2018–2023 · strength 0.70
  17. Hao Li · 6 shared papers, 2018–2023 · strength 0.67
  18. Yuquan Guo · 3 shared papers, 2024–2025 · strength 0.63
  19. Shirong Zhang · 6 shared papers, 2018–2023 · strength 0.62
  20. Jin Xu · 11 shared papers, 2013–2019 · strength 0.59
  21. Long‐Yun Ye · 5 shared papers, 2020–2022 · strength 0.57
  22. Hanlin Yin · 3 shared papers, 2023–2025 · strength 0.56
  23. Wenhui Lou · 3 shared papers, 2023–2025 · strength 0.56
  24. Jiang Long · 10 shared papers, 2013–2020 · strength 0.55
  25. Liang Liu · 3 shared papers, 2023–2025 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.